^
Association details:
| Biomarker: | ZG16B positive |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | ulenistamab (PBP1510) (ZG16B inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3P - Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb)
Published date:
03/03/2022
Excerpt:
Superior anti-tumour efficacy of PBP1510 treatment, compared to IgG control, was observed in all the three mouse models, particularly in PAUF-positive cancer models...The current efficacy and safety data, along with other pre-clinical data, support further clinical development of PBP1510 as a novel anti-cancer agent to treat PAUF-positive PC.